Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q92731
UPID:
ESR2_HUMAN
Alternative names:
Nuclear receptor subfamily 3 group A member 2
Alternative UPACC:
Q92731; A8K8K5; G3V5M5; O60608; O60685; O60702; O60703; O75583; O75584; Q0MWT5; Q0MWT6; Q86Z31; Q9UEV6; Q9UHD3; Q9UQK9
Background:
Estrogen receptor beta, also known as Nuclear receptor subfamily 3 group A member 2, plays a crucial role in gene expression regulation by binding estrogens. It shares similarities with ESR1/ER-alpha in estrogen affinity, activating genes with estrogen response elements in a dependent manner. However, it lacks ligand binding ability, significantly impacting its function.
Therapeutic significance:
Linked to Ovarian dysgenesis 8, a condition marked by primary amenorrhea and hypergonadotropic hypogonadism, understanding the role of Estrogen receptor beta could unveil new therapeutic strategies. Its involvement suggests potential for targeted treatments in reproductive disorders.